New Study: Herpes Zoster May Lead to Stroke; polyDNA Recommends Gene-Eden-VIR against VZV

Since 1 out of every 3 people in the United States will develop shingles, polyDNA recommends Gene-Eden-VIR to kill VZV as early as possible.

Rochester, NY (PRWEB) April 23, 2013

In a new study from the Journal of Neurovirology it was found that "Virological confirmation of varicella zoster virus (VZV) vasculopathy is provided by presence of virus in the cerebral arteries. Thus, the presence of VZV antigen in cerebral arteries of patients with stroke is likely to be clinically significant."(1)

In simple terms this means that the connection between the herpes zoster virus and suffering a stroke is very important.

Another study also reported that a herpes zoster attack lowers the survival rate. (2)

This is important information since, “…1 out of every 3 people in the United States will develop shingles, also known as zoster or herpes zoster.” (3) In fact, anyone who has ever had chickenpox is at risk for developing herpes zoster. Even children can develop this affliction after a case of chickenpox. However, “the risk of disease increases as a person gets older” (3) as does the risk of suffering a debilitating stroke.

The public, especially those over the age of 65, should be aware of the dangers and risks of a herpes zoster attack. polyDNA recommends that these individuals educate themselves about Gene-Eden-VIR, a natural remedy designed to boost the immune system against latent VZV.

“Since VZV is the only recognized human virus able to replicate in cerebral arteries, (4) I feel like anyone with an increased risk of developing shingles should consider doing what they can to reduce the levels of VZV virus in their systems. No one wants to suffer a stroke.” – Mike Evans, polyDNA

Currently, doctors only prescribe Blood platelet inhibitors such as Aspirin, Dipyridamole, Ticlopidine, Clopidogrel and Sulfinpyrazone are effective in reducing the risk for stroke.(5) However, these are for thinning the blood and are used to help prevent blood clots from forming inside arteries in the brain. These drugs do nothing against the herpes zoster virus.

In contrast, Gene-Eden-VIR was designed to boost the immune system against viruses like latent VZV. "The key to your health is to reduce the level of the latent viruses in your body to harmless levels." - Dr. Hanan Polansky

In a post marketing clinical study, Gene-Eden-VIR was shown to be safe and highly effective against the latent herpes zoster virus. Over 70% of Gene-Eden-VIR users reported a reduction in VZV symptoms. (6)

Each capsule of Gene-Eden-VIR contains a patented formula of five all natural ingredients including selenium, camellia sinesis extract, quercetin, cinnamomum extract, and licorice extract. In addition, each bottle is GMP Certified. (7)

To learn more about Gene-Eden-VIR, the only product on the market today that helps the body target the latent herpes zoster virus and that is scientifically backed by published material, visit http://www.gene-eden-kill-virus.com.

References:

(1) http://www.ncbi.nlm.nih.gov/pubmed/23456953

(2) http://f1000.com/prime/1165403

(3) http://www.cdc.gov/shingles/about/overview.html

(4) Kleinschmidt-DeMasters BK, Gilden DH. Varicella-zoster virus infections of the nervous system: clinical and pathologic correlates. Arch Pathol Lab Med. 2001; 125: 770–780.

(5) http://www.medicalnewstoday.com/articles/184601.php

(6) http://www.cbcd.net/Gene-Eden-VIR-Clinical-Study.php

(7) http://www.gene-eden-kill-virus.com/studies.php

polyDNA is a biotechnology company that develops dietary supplements using the unique scientific method developed by Dr. Hanan Polansky, which is based on Computer Intuition.

In addition to his unique scientific method, Dr. Polansky published the highly acclaimed scientific discovery called Microcompetition with Foreign DNA.

The discovery explains how foreign DNA fragments and specifically DNA of latent viruses cause most major diseases. polyDNA developed Gene-Eden-VIR, an antiviral natural remedy that helps the immune system kill latent viruses.

Mike Davis
PolyDNA
5852509999
Email Information

View the original article here

Shingles Raises Risk Of Stroke By 30 Percent Or More In Adults, Study Finds

ScienceDaily (Oct. 9, 2009) — Adults with shingles were about 30 percent more likely to have a stroke during a one-year follow-up than adults without shingles, in a study reported in Stroke: Journal of the American Heart Association.

The risk was even greater when the infection involved the eyes.

Shingles, also called herpes zoster, is a painful skin rash caused by the varicella zoster virus (VZV). VZV is the same virus that causes chickenpox. After a person recovers from chickenpox, the virus stays in the body. Usually the virus doesn’t cause problems, but it can reappear years later, causing shingles.

Shingles is not caused by the same virus that causes genital herpes, a sexually transmitted disease.

“Many studies have shown that people with herpes zoster infection are more likely to develop stroke. But ours is the first to demonstrate the actual risk of stroke following herpes zoster infection,” said Jiunn-Horng Kang, M.D., M.Sc., lead author of the study and attending physician in the Department of Physical Medicine and Rehabilitation and chair of the Sleep Physiological Lab at Taipei Medical University Hospital.

Kang and his associates studied 7,760 patients 18 years and older who received shingles treatment between 1997 and 2001. These people were matched by age and gender with 23,280 adults who weren’t treated for shingles (controls). Their average age was 47.

During the one-year follow-up, 133 shingles patients (about 1.7 percent) and 306 of the controls (about 1.3 percent) had strokes. After adjusting for general factors for stroke risk, the researchers found:

People treated for a shingles infection were 31 percent more likely to have a stroke, compared with patients without a shingles infection.Patients with shingles infections that involved the skin around the eye and the eye itself (herpes zoster ophthalmicus) were 4.28 times more likely to have a stroke than patients without shingles. When the researchers analyzed the risk of stroke by stroke type, they found:Shingles patients were 31 percent more likely to develop an ischemic stroke during the one-year follow-up than those without shingles.The risk of hemorrhagic (bleeding) stroke was 2.79 times higher for people with shingles infection than for people without shingles.

Ischemic strokes, which are caused by the blockage of an artery, account for 87 percent of the new or recurrent strokes that strike about 780,000 Americans annually, according to the American Heart Association.

“Herpes zoster infection is very easy to diagnose, and antiviral medication can be used to treat the infection in the early stages,” Kang said. “While the mechanism by which shingles increases stroke risk remains unclear, the possibility of developing a stroke after a shingles attack should not be overlooked.

Doctors and patients must pay extra attention to controlling other risk factors for stroke, such as high blood pressure, smoking and diabetes.”

Shingles usually starts as a rash on one side of the face or body. The rash starts as blisters that scab after three to five days and usually clears within two to four weeks. There is often pain, itching or tingling in the area where the rash develops.

Researchers didn’t design the study to determine how shingles infection raises stroke risk. But other research suggests that as the herpes zoster virus replicates and attacks the vessel wall, the vessel wall becomes damaged and inflamed. This in turn can cause the vessel to close up, or occlude, blocking blood flow to the brain. Shingles is also the only recognized human virus able to invade cerebral arteries.

In addition, shingles is also associated with severe pain, and the stress of that chronic pain may raise the risk of cardiovascular disease theoretically, Kang said.

Co-authors are Jau-Der Ho, M.D., Ph.D.; Yi-Hua Chen, Ph.D.; and Herng-Ching Lin, Ph.D. Individual author disclosures are on the manuscript.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by American Heart Association.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.

View the original article here

Exposure to several common infections over time may be associated with risk of stroke

ScienceDaily (Nov. 9, 2009) — Cumulative exposure to five common infection-causing pathogens may be associated with an increased risk of stroke, according to a report posted online today that will appear in the January 2010 print issue of Archives of Neurology, one of the JAMA/Archives journals.

Stroke is the third leading cause of death and leading cause of serious disability in the United States, according to background information in the article. Known risk factors include high blood pressure, heart disease, abnormal cholesterol levels and smoking, but many strokes occur in patients with none of these factors. "There is therefore interest in identifying additional modifiable risk factors," the authors write.

Some evidence exists that prior infection with pathogens such as herpes viruses promotes inflammation, contributes to arterial disease and thereby increases stroke risk. Mitchell S. V. Elkind, M.D., M.S., of Columbia University Medical Center, New York, and colleagues studied 1,625 adults (average age 68.4) living in the multi-ethnic urban community of northern Manhattan, New York. Blood was obtained from all participants -- none of whom had a stroke -- and was tested for antibodies indicating prior exposure to five common pathogens: Chlamydia pneumoniae, Helicobacter pylori, cytomegalovirus and herpes simplex virus 1 and 2. A weighted composite index of exposure to all five pathogens was developed.

Participants were followed up annually over a median (midpoint) of 7.6 years. During this time period, 67 had strokes. "Each individual infection was positively, though not significantly, associated with stroke risk after adjusting for other risk factors," the authors write. "The infectious burden index was associated with an increased risk of all strokes after adjusting for demographics and risk factors."

There were several reasons to investigate these five particular pathogens, the authors note. "First, each of these common pathogens may persist after an acute infection and thus contribute to perpetuating a state of chronic, low-level infection," they write. "Second, prior studies demonstrated an association between each of these pathogens and cardiovascular diseases." Studies examining several of these pathogens individually have suggested some may contribute to stroke risk.

"Our study could have potential clinical implications," the authors conclude. "For example, treatment and eradication of these chronic pathogens might mitigate future risk of stroke. Antibiotic therapy directed against C pneumoniae has been tested in randomized controlled trials without evidence of benefit against heart disease. Whether the same holds true for stroke has not yet been established. More studies will be required to further explore infectious burden as a potential modifiable risk factor for stroke."

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by JAMA and Archives Journals.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Journal Reference:

Elkind et al. Infectious Burden and Risk of Stroke: The Northern Manhattan Study. Archives of Neurology, 2009; DOI: 10.1001/archneurol.2009.271

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.

View the original article here